retatrutide eli lilly press release 2024 2025 Lilly's Experimental Diabetes Drug Shows Promise for Weight Loss A new clinical trial from

Persistent nausea, early satiety, bloating, or constipation may lead to reduced treatment satisfaction and contribute to therapy interruption or discontinuation

Current medications like Zepbound and Wegovy range from $1,000 to $1,500 monthly

Whilst significant weight loss achieved through semaglutide therapy can reduce suprapubic fat and reveal more of the penile shaft previously obscured, this represents an optical change rather than actual tissue growth

For context on managing these effects, the approaches used for GLP-1 constipation and GLP-1 bloating apply here with some modifications

GLP-1 regulates feeding behavior, glycemic control, and stress [21]

Diabetes Care , 36(4), 10231030